Matthew J Olnes

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leuk Res 36:982-9. 2012
  2. pmc Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors
    Matthew J Olnes
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 52:537-41. 2012
  3. doi request reprint Targeting immune dysregulation in myelodysplastic syndromes
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, and Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bldg 10 CRC 3 1341, Bethesda, MD 20892, USA
    JAMA 305:814-9. 2011
  4. pmc Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
    Ronan Desmond
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
    Blood 123:1818-25. 2014
  5. pmc Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
    J Clin Oncol 28:5166-73. 2010
  6. pmc T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
    Elaine M Sloand
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 117:2691-9. 2011
  7. doi request reprint Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
    Ankur R Parikh
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Semin Hematol 49:304-11. 2012
  8. pmc Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
    Sawa Ito
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Mol Ther 22:1388-95. 2014
  9. ncbi request reprint Global analyses of human immune variation reveal baseline predictors of postvaccination responses
    John S Tsang
    Trans NIH Center for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Bethesda, MD 20892, USA Systems Genomics and Bioinformatics Unit, Laboratory of Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA Electronic address
    Cell 157:499-513. 2014
  10. pmc Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab
    Elaine M Sloand
    National Heart Lung and Blood Instititute, NIH, Bethesda, MD 20892, USA
    Haematologica 95:382-7. 2010

Collaborators

Detail Information

Publications12

  1. pmc Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leuk Res 36:982-9. 2012
    ..Knockdown" of cyclin D1 by RNA interference decreased trisomy 8 cell growth, suggesting that this might be a therapeutic target in MDS...
  2. pmc Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors
    Matthew J Olnes
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 52:537-41. 2012
    ..However, there are no studies addressing whether repeated administration of G-CSF produces Monosomy 7 aneuploidy in healthy donors...
  3. doi request reprint Targeting immune dysregulation in myelodysplastic syndromes
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, and Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bldg 10 CRC 3 1341, Bethesda, MD 20892, USA
    JAMA 305:814-9. 2011
    ..In this article, we review the pathobiology of immune dysregulation in MDS and summarize the role of immunosuppressive therapy in MDS...
  4. pmc Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
    Ronan Desmond
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
    Blood 123:1818-25. 2014
    ..This study is registered at www.clinicaltrials.gov as #NCT00922883. ..
  5. pmc Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
    J Clin Oncol 28:5166-73. 2010
    ..Because of the toxicities associated with h-ATG/CsA, we investigated an alternative regimen with alemtuzumab in MDS...
  6. pmc T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
    Elaine M Sloand
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 117:2691-9. 2011
    ..Thus, our results suggest that WT1 is one of the antigens that triggers T cell-mediated myelosuppression in MDS...
  7. doi request reprint Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
    Ankur R Parikh
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Semin Hematol 49:304-11. 2012
    ....
  8. pmc Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
    Sawa Ito
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Mol Ther 22:1388-95. 2014
    ..This is the first study to evaluate global immune-modulating function of ULD IL-2 in healthy subjects and to support the future studies administrating ULD IL-2 to stem cell donors. ..
  9. ncbi request reprint Global analyses of human immune variation reveal baseline predictors of postvaccination responses
    John S Tsang
    Trans NIH Center for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Bethesda, MD 20892, USA Systems Genomics and Bioinformatics Unit, Laboratory of Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA Electronic address
    Cell 157:499-513. 2014
    ..Most of the parameters contributing to prediction delineated temporally stable baseline differences across individuals, raising the prospect of immune monitoring before intervention. ..
  10. pmc Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab
    Elaine M Sloand
    National Heart Lung and Blood Instititute, NIH, Bethesda, MD 20892, USA
    Haematologica 95:382-7. 2010
    ....
  11. pmc Eltrombopag and improved hematopoiesis in refractory aplastic anemia
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 367:11-9. 2012
    ..Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells...
  12. pmc Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects
    Angelique Biancotto
    Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e76091. 2013
    ..In this study, we use multiplex bead arrays to evaluate 27 analytes in paired serum samples taken seven days apart from 144 healthy individuals in order to assess variations over a short time period...